Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
175
-
Total 13F shares, excl. options
-
67.5M
-
Shares change
-
+11.4M
-
Total reported value, excl. options
-
$1.82B
-
Value change
-
+$325M
-
Put/Call ratio
-
0.39
-
Number of buys
-
109
-
Number of sells
-
-58
-
Price
-
$27.00
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2022
215 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2022.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 175 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67.5M shares
of 105M outstanding shares and own 64.53% of the company stock.
Largest 10 shareholders include Capital World Investors (8.05M shares), BlackRock Inc. (6.13M shares), JPMORGAN CHASE & CO (5.45M shares), Polar Capital Holdings Plc (4.46M shares), Palo Alto Investors LP (4.41M shares), VANGUARD GROUP INC (4.31M shares), FRANKLIN RESOURCES INC (2.39M shares), FMR LLC (1.75M shares), BAMCO INC /NY/ (1.72M shares), and STATE STREET CORP (1.62M shares).
This table shows the top 175 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.